Hims & Hers Q4: A Beat on the Bottom Line, But Guidance Resets the Expectation Gap

The numbers for Hims & Hers' fourth quarter were a classic case of meeting one expectation while missing another. Revenue came in at $617.8 million, a figure that met the whisper number and represented a solid 28.4% year-over-year growth. More importantly, the bottom line crushed estimates, with GAAP EPS of $0.08 per share beating the Street's forecast by a massive 92.5%. On paper, this looks like a clean beat-and-raise scenario.

Yet the stock fell about 2% in after-hours trading, a textbook "sell the news" reaction. The disconnect was immediate and clear. The company's guidance for the upcoming quarter reset the expectation gap. Q1 revenue guidance of $612.5 million came in 5.6% below analysts' estimates. More broadly, the full-year 2026 revenue outlook of $2.7 billion to $2.9 billion trails the Street's consensus of $2.74 billion. The beat on the bottom line was priced in; the miss on the forward view was not.

This is the game of expectations in action. The market had baked in strong momentum, and the guidance reset signaled a potential deceleration. The stock's decline shows that even a stellar quarterly print can disappoint if the forward path looks less certain.

The Guidance Reset: Sandbagging or Structural Shift?

The lowered guidance isn't just a minor tweak; it's a significant reset that forces a re-evaluation of the business trajectory. The full-year 2026 Adjusted EBITDA outlook of $300 million to $375 million sits below the $369 million analyst consensus. More telling is the midpoint: $337.5 million, which represents a notable reduction from the implied path based on last year's results. This isn't a simple sandbagging tactic for a clean beat; it's a structural shift in the forward expectation gap.

The financial health metrics underscore this shift. The company's free cash flow swung to a loss of $2.6 million in Q4, a dramatic reversal from the $59.5 million profit it posted a year ago. This cash flow deterioration, coupled with the EBITDA guidance reset, paints a picture of a business under pressure. The market's "sell the news" reaction makes sense in this light. The stellar bottom-line beat was already priced in, but the guidance now signals that the path to profitability is getting steeper, not easier.

The context of legal troubles and regulatory overhang adds another layer of uncertainty. The company's outlook assumes it can continue selling copycat weight-loss drugs, a scenario now clouded by a patent lawsuit and potential DOJ charges. In this environment, a conservative EBITDA guide may be prudent planning, but it also reflects a loss of visibility. The stock's decline is the market's verdict: it's pricing in a more challenging operational and legal reality than the quarter's numbers suggested.

The External Pressure: A New Risk to the Growth Narrative

The guidance reset wasn't the only shock to the system. A major external catalyst has emerged that directly attacks a core pillar of Hims & Hers' recent growth story. Earlier this month, Novo Nordisk filed a patent infringement lawsuit against the company, targeting its compounded Wegovy copy. This legal and regulatory pressure comes at a critical juncture, following the FDA's determination that semaglutide is no longer in short supply. That shift, which experts say has reduced the public backlash risk for patent enforcement, undermines the very regulatory loophole that allowed Hims' rapid expansion into the weight-loss drug market.

The company's own actions underscore the severity of the threat. In response to the lawsuit and regulatory scrutiny, Hims said it will stop offering its newly launched obesity pill copycat. This retreat from a key product launch, just days after its planned $49-a-month entry, is a stark admission of vulnerability. The lawsuit seeks to permanently ban sales of compounded versions of Novo's drugs, a direct assault on a well-established, vital component of US pharmacy practice that Hims has relied on for patient access and revenue.

This external pressure interacts with the guidance reset and the "sell the news" dynamic in a dangerous way. The lowered financial outlook already signaled a more challenging path. Now, a major growth driver-the mass compounding of GLP-1 drugs-is facing a legal and regulatory headwind that could materially shrink the addressable market. The stock's sharp decline on the news of the lawsuit, which followed the earnings report, shows the market is pricing in this new risk. It's not just about one quarter's numbers; it's about the durability of the growth narrative itself.

Catalysts and What to Watch: The Path to a New Consensus

The stock's pessimistic reaction has set a new baseline. The path to a new consensus will be determined by a few key catalysts that will either validate the reset guidance or prove the sell-off was overdone. The first major test arrives in May with the Q1 results. The market will be watching to see if the company can meet or beat its lowered revenue guidance of $612.5 million. Success here would confirm the guidance was a prudent, not a panicked, reset. A miss, however, would signal the deceleration is worse than feared, likely keeping downward pressure on the stock.

Simultaneously, the Novo Nordisk lawsuit remains a live wire. Any update on regulatory actions or court rulings could force further business model changes. The company's swift retreat from its new obesity pill copycat is a clear sign of vulnerability. The market will be watching for any indication that the legal threat extends beyond that single product, potentially impacting the broader compounding business that has been a key growth lever. This is a direct test of the durability of the growth narrative that the earnings report initially seemed to confirm.

Most critically, investors must monitor the health of the core engine: subscriber growth. The company's subscriber base grew to over 2.5 million, but the growth rate slowed to 13% year-over-year in 2025. This deceleration in the customer base is a leading indicator for future revenue. If the Q1 results show subscriber growth stagnating or declining, it would directly undermine the revenue guidance and confirm the expectation gap is widening. Conversely, a rebound in growth would suggest the company is effectively navigating the new headwinds.

The bottom line is that the current setup is a waiting game between two narratives. The bear case hinges on the guidance being too optimistic and the legal overhang being material. The bull case requires the company to execute flawlessly on its lowered targets while the legal battle is resolved in its favor. The next few months will provide the evidence to decide which story is priced in.